Abelacimab  (Synonyms: 阿贝西单抗; MAA868)

Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies^[1][2].

Human IgG1 lambda1

Human IgG1 lambda1, Isotype Control

Abelacimab (MAA868) (0.0001-1 μM) 以浓度依赖的方式延长凝血时间并减少人血浆中的凝血酶数量^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Abelacimab (MAA868) (s.c., 3-30 mg/kg, on day 1, 85, 114) 在食蟹猴中表现出强烈和持续的抗凝血作用，显着延长 aPTT，且具有较好的安全性，未观察到显着的毒性发现或出血迹象^[1]。
Abelacimab (MAA868) (i.v., 0.6 mg/kg) 在氯化铁诱导的血栓形成 FXI^-/- C57BL/6 小鼠模型中表现出良好的抗凝血活性，以防止颈动脉阻塞^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2098724-83-3

液体

Colorless to light yellow

阿贝西单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda2

• 
  Immobilized Human Factor XI Protein (His Tag) can bind Abelacimab. The EC₅₀ for this effect is 1.40 ng/mL.

• [1]. Alexander W Koch, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019 Mar 28;133(13):1507-1516.  [Content Brief]

  [2]. Elena Campello, et al. Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders. J Clin Med. 2022 Oct 26;11(21):6314.  [Content Brief]